{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:05:15Z","timestamp":1792008315399,"version":"4.4.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.jaad.2008.06.004","type":"journal-article","created":{"date-parts":[[2008,7,25]],"date-time":"2008-07-25T04:40:55Z","timestamp":1216960855000},"page":"633-653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Raynaud's phenomenon: Pathogenesis and management"],"prefix":"10.1016","volume":"59","author":[{"given":"Richard","family":"Bakst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Andrew G.","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2008.06.004_bib1","series-title":"Translated by Barlow","article-title":"Local asphyxia and symmetrical gangrene of extremities 1862. New researches on the nature and treatment of local asphyxia of the extremities 1874","author":"Raynaud","year":"1888"},{"key":"10.1016\/j.jaad.2008.06.004_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0021-9681(86)90109-8","article-title":"Prevalence of Raynaud phenomenon in the general population: a preliminary study by questionnaire","volume":"39","author":"Maricq","year":"1986","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/art.1780390717","article-title":"Familial aggregation of primary Raynaud's disease","volume":"39","author":"Freedman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11926-002-0007-z","article-title":"Raynaud's phenomenon: epidemiology and risk factors","volume":"4","author":"Fraenkel","year":"2002","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaad.2008.06.004_bib5","first-page":"879","article-title":"Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison","volume":"24","author":"Maricq","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib6","first-page":"403","article-title":"Raynaud's phenomenon","volume":"123","author":"Hutchison","year":"1901","journal-title":"Med Press"},{"key":"10.1016\/j.jaad.2008.06.004_bib7","first-page":"7","article-title":"Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease","volume":"15","author":"Lewis","year":"1929","journal-title":"Heart"},{"key":"10.1016\/j.jaad.2008.06.004_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00000441-193202000-00004","article-title":"Raynaud's disease: a critical review of minimal requisites for diagnosis","volume":"183","author":"Allen","year":"1932","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaad.2008.06.004_bib9","first-page":"485","article-title":"Raynaud's phenomenon: a proposal for classification","volume":"10","author":"LeRoy","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0889-857X(03)00019-X","article-title":"Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma","volume":"29","author":"Hummers","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2008.06.004_bib11","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud's phenomenon","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.06.004_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0049-0172(94)90098-1","article-title":"Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma","volume":"24","author":"ter Borg","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.47.8.634","article-title":"Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting","volume":"47","author":"Kallenberg","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-9343(97)00023-5","article-title":"Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies","volume":"103","author":"Spencer-Green","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0741-5214(05)80037-0","article-title":"Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort","volume":"23","author":"Landry","year":"1996","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jaad.2008.06.004_bib16","first-page":"327","article-title":"Observations upon maladies in which the blood supply to the digits cease intermittently or permanently, and upon bilateral gangrene of digits; observations relevant to so-called Raynaud's disease","volume":"1","author":"Lewis","year":"1934","journal-title":"Clin Sci"},{"key":"10.1016\/j.jaad.2008.06.004_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib18","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/art.11060","article-title":"Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease","volume":"48","author":"Rajagopalan","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib19","first-page":"314","article-title":"Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis","volume":"25","author":"Yamamoto","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2249.2003.02320.x","article-title":"Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features","volume":"134","author":"Takagi","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2008.06.004_bib21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/rheumatology\/41.8.843","article-title":"Beauty and the beast: the nitric oxide paradox in systemic sclerosis","volume":"41","author":"Matucci Cerinic","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/rheumatology\/kei276","article-title":"Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine","volume":"45","author":"Dooley","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib23","first-page":"312","article-title":"Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling","volume":"221","author":"Kirchengast","year":"1999","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2165\/00003495-199346050-00001","article-title":"Endothelins: vascular actions and clinical implications","volume":"46","author":"Sakurai","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2008.06.004_bib25","first-page":"1268","article-title":"Localization of endothelin-1 and its binding sites in scleroderma skin","volume":"21","author":"Vancheeswaran","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0140-6736(90)92766-B","article-title":"Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon","volume":"336","author":"Zamora","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.06.004_bib27","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.59.11.870","article-title":"Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon","volume":"59","author":"Smyth","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/01.hjh.0000226182.60321.69","article-title":"Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review","volume":"24","author":"Duprez","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.jaad.2008.06.004_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.11364","article-title":"Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors","volume":"50","author":"Kawaguchi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/rheumatology\/35.11.1127","article-title":"Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis","volume":"35","author":"Bukhari","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1358863x05vm639ra","article-title":"Mechanisms of Raynaud's disease","volume":"10","author":"Cooke","year":"2005","journal-title":"Vasc Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0889-857X(05)70300-8","article-title":"Raynaud's phenomenon","volume":"22","author":"Wigley","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2008.06.004_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-200011000-00009","article-title":"Vascular function in systemic sclerosis","volume":"12","author":"Herrick","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archderm.1988.01670090035007","article-title":"Cutaneous hypoxia in patients with systemic sclerosis (scleroderma)","volume":"124","author":"Silverstein","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2133.1992.tb00100.x","article-title":"Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy","volume":"126","author":"Freemont","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711660307","article-title":"Sequential dermal microvascular and perivascular changes in the development of scleroderma","volume":"166","author":"Prescott","year":"1992","journal-title":"J Pathol"},{"key":"10.1016\/j.jaad.2008.06.004_bib37","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1529-0131(200011)43:11<2550::AID-ANR24>3.0.CO;2-H","article-title":"Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95","volume":"43","author":"Sgonc","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.jaad.2008.06.004_bib38","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1016\/0895-7061(95)00030-S","article-title":"Endothelial cell signaling and endothelial dysfunction","volume":"8","author":"Flavahan","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jaad.2008.06.004_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0889-857X(05)70295-7","article-title":"Systemic sclerosis: a vascular perspective","volume":"22","author":"LeRoy","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2008.06.004_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0889-857X(03)00021-8","article-title":"The vasculopathy of Raynaud's phenomenon and scleroderma","volume":"29","author":"Flavahan","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2008.06.004_bib41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1","article-title":"Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis","volume":"42","author":"Rajkumar","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib42","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/bmj.287.6404.1499","article-title":"Role of cold and emotional stress in Raynaud's disease and scleroderma","volume":"287","author":"Freedman","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jaad.2008.06.004_bib43","first-page":"84","article-title":"Vascular and humoral sympathetic nervous system reactivity during mental arithmetic in primary Raynaud's phenomenon","volume":"9","author":"Droste","year":"1990","journal-title":"Int Angiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/17.11.671","article-title":"Digital vasodilatation during mental stress in patients with Raynaud's disease","volume":"17","author":"Halperin","year":"1983","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaad.2008.06.004_bib45","first-page":"316","article-title":"Cutaneous circulation in Raynaud's phenomenon during emotional stress: a morphological and functional study using capillaroscopy and laser-Doppler","volume":"11","author":"Martinez","year":"1992","journal-title":"Int Angiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/cs0950249","article-title":"Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease","volume":"95","author":"Edwards","year":"1998","journal-title":"Clin Sci (Colch)"},{"key":"10.1016\/j.jaad.2008.06.004_bib47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02319455","article-title":"The cutaneous vasoconstrictor response to venous stasis is normal in subjects with primary Raynaud's disease","volume":"9","author":"Edwards","year":"1999","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.jaad.2008.06.004_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.1996.tb16221.x","article-title":"Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon","volume":"134","author":"Bunker","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib49","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-B","article-title":"Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon","volume":"336","author":"Bunker","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.06.004_bib50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0140-6736(93)91286-U","article-title":"Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon","volume":"342","author":"Bunker","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.06.004_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rdc.2004.10.005","article-title":"Estrogens and neuropeptides in Raynaud's phenomenon","volume":"31","author":"Generini","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2008.06.004_bib52","doi-asserted-by":"crossref","first-page":"H1404","DOI":"10.1152\/ajpheart.00061.2004","article-title":"Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans","volume":"287","author":"Stephens","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(25)24862-5","article-title":"Effect of cooling on alpha-1 and alpha-2 adrenergic responses in canine saphenous and femoral veins","volume":"238","author":"Flavahan","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2008.06.004_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-5347(25)00268-X","article-title":"Human postjunctional alpha-1 and alpha-2 adrenoreceptors: differential distribution in arteries of the limbs","volume":"241","author":"Flavahan","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2008.06.004_bib55","doi-asserted-by":"crossref","first-page":"H1075","DOI":"10.1152\/ajpheart.2000.278.4.H1075","article-title":"Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries","volume":"278","author":"Chotani","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/mol.60.6.1195","article-title":"Cooling evokes redistribution of alpha2C-adrenoreceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells","volume":"60","author":"Jeyaraj","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaad.2008.06.004_bib57","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/01.RES.0000128407.45014.58","article-title":"Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation","volume":"94","author":"Bailey","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jaad.2008.06.004_bib58","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.01305.2004","article-title":"Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries","volume":"289","author":"Bailey","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib59","doi-asserted-by":"crossref","first-page":"H69","DOI":"10.1152\/ajpheart.01223.2003","article-title":"Distinct cAMP signaling pathways differently regulate alpha2C\u2013adrenoreceptor expression: role in serum induction in human arteriolar smooth muscle cells","volume":"288","author":"Chotani","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib60","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/art.20214","article-title":"Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease","volume":"50","author":"Furspan","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib61","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/rheumatology\/keh517","article-title":"Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon","volume":"44","author":"Furspan","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib62","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/1529-0131(200007)43:7<1641::AID-ANR30>3.0.CO;2-Y","article-title":"A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon","volume":"43","author":"Susol","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0738-081X(94)90293-3","article-title":"Cytokines and systemic sclerosis","volume":"12","author":"Fagundus","year":"1994","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/03009749309099251","article-title":"Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis","volume":"22","author":"Lau","year":"1993","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/030097401753180372","article-title":"Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis","volume":"30","author":"Silveri","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib66","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/jcp.37.2.182","article-title":"Assessment of platelet function in patients with Raynaud's syndrome","volume":"37","author":"Hutton","year":"1984","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jaad.2008.06.004_bib67","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/bmj.292.6527.1037","article-title":"Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon","volume":"292","author":"Reilly","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jaad.2008.06.004_bib68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0167-5273(88)90238-0","article-title":"Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon","volume":"19","author":"Biondi","year":"1988","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/ard.55.2.122","article-title":"Von Willebrand factor, thrombomodulin, thromboxane, b-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis","volume":"55","author":"Herrick","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/cs0860269","article-title":"Plasma levels of 5-hydroxtryptamine during sympathetic stimulation and in Raynaud's phenomenon","volume":"86","author":"Coffman","year":"1994","journal-title":"Clin Sci (Colch)"},{"key":"10.1016\/j.jaad.2008.06.004_bib71","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/ard.52.6.443","article-title":"Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon","volume":"52","author":"Lau","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib72","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/rheumatology\/36.10.1045","article-title":"The coagulation\/fibrinolysis balance in systemic sclerosis: evidence for a hematological stress syndrome","volume":"36","author":"Ames","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib73","first-page":"4","article-title":"The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis","volume":"19","author":"Herrick","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib74","first-page":"1477","article-title":"Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis","volume":"21","author":"Herrick","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.7326\/0003-4819-129-3-199808010-00009","article-title":"The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women","volume":"129","author":"Fraenkel","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1042\/cs0680639","article-title":"Reflex vascular responses in the finger to contralateral thermal stimuli during the normal menstrual cycle: a hormonal basis to Raynaud's phenomenon?","volume":"69","author":"Lafferty","year":"1985","journal-title":"Clin Sci (Colch)"},{"key":"10.1016\/j.jaad.2008.06.004_bib77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2170\/jjphysiol.53.193","article-title":"Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries","volume":"53","author":"Momoi","year":"2003","journal-title":"Jpn J Physiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib78","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/01.RES.0000111525.96232.46","article-title":"Estrogen elicits cytochrome P450-mediated flow-induced dilation of arterioles in NO deficiency: role of PI3K-Akt phosphorylation in genomic regulation","volume":"94","author":"Huang","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jaad.2008.06.004_bib79","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0002-9149(98)00708-5","article-title":"Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis","volume":"82","author":"Lekakis","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib80","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0002-8703(98)70137-1","article-title":"Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon","volume":"136","author":"Lekakis","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.jaad.2008.06.004_bib81","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/rheumatology\/38.11.1094","article-title":"A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon","volume":"38","author":"Smyth","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib82","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/art.11220","article-title":"Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence","volume":"48","author":"Zhou","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/j.1552-4604.1982.tb05712.x","article-title":"The treatment of severe Raynaud's phenomenon with verapamil","volume":"22","author":"Kinney","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2008.06.004_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(85)90168-8","article-title":"Treatment of Raynaud's phenomenon with calcium channel blockers","volume":"78","author":"Smith","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib85","doi-asserted-by":"crossref","first-page":"154B","DOI":"10.1016\/0002-9149(85)90625-3","article-title":"Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers","volume":"55","author":"Smith","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib86","first-page":"724","article-title":"A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon","volume":"12","author":"Rhedda","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7326\/0003-4819-95-2-243_2","article-title":"Calcium channel blockers and Raynaud's disease","volume":"95","author":"Vayssairat","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib88","first-page":"858","article-title":"Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study","volume":"14","author":"da Costa","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib90","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib91","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archinte.160.8.1101","article-title":"Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up","volume":"160","author":"Fredrick","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib92","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/art.1780280504","article-title":"Nifedipine and esophageal dysfunction in progressive systemic sclerosis: a controlled manometric study","volume":"28","author":"Kahan","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib93","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1001\/jama.284.24.3160","article-title":"Pulmonary hypertension","volume":"284","author":"Gaine","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2008.06.004_bib94","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon","volume":"34","author":"Teh","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(82)90215-X","article-title":"Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease","volume":"1","author":"Franks","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.06.004_bib96","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.1780400220","article-title":"Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon","volume":"40","author":"Khan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib97","first-page":"2389","article-title":"Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation","volume":"26","author":"Khan","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib98","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(99)03557-6","article-title":"Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma","volume":"354","author":"Freedman","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.06.004_bib99","first-page":"321","article-title":"Pulmonary hypertension\u2013beyond vasodilator therapy","volume":"338","author":"Fishman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI12020","article-title":"Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients","volume":"108","author":"Stratton","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2008.06.004_bib101","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib102","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib103","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib104","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/rheumatology\/keg480","article-title":"Safety and efficacy of iloprost for the treatment of ischemic digits in pediatric connective tissue diseases","volume":"43","author":"Zulian","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib106","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/bmj.281.6247.1031","article-title":"Treatment of vasospastic disease with prostaglandin E1","volume":"281","author":"Clifford","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.jaad.2008.06.004_bib107","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"18","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaad.2008.06.004_bib108","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/37.9.952","article-title":"Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study","volume":"37","author":"Black","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib109","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","article-title":"Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"41","author":"Wigley","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib110","first-page":"1917","article-title":"Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon: French Microcirculation Society multicenter group for the study of vascular acrosyndromes","volume":"23","author":"Vayssairat","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib111","first-page":"2173","article-title":"Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis: French Microcirculation Society multicenter group for the study of vascular acrosyndromes","volume":"26","author":"Vayssairat","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib112","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib113","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.10628","article-title":"Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson, et al","volume":"28","author":"Lichtenstein","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib114","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/ard.2003.015677","article-title":"Sever digital ischemia treated with phosphodiesterase inhibitors","volume":"63","author":"Kumana","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib115","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2008.06.004_bib116","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","article-title":"Effects of cilostazol in patients with Raynaud's syndrome","volume":"92","author":"Rajagopalan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib117","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.CIR.94.3.258","article-title":"Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (trial on reversing endothelial dysfunction) study","volume":"94","author":"Mancini","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2008.06.004_bib118","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000174908","article-title":"Cardioreparation with lisinopril in the management of hypertension and heart failure","volume":"79","author":"Weber","year":"1991","journal-title":"Cardiology"},{"key":"10.1016\/j.jaad.2008.06.004_bib119","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1991.tb05565.x","article-title":"Subjective and objective assessment of enalapril in primary Raynaud's phenomenon","volume":"31","author":"Challenor","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2008.06.004_bib120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","article-title":"Enalapril in Raynaud's phenomenon","volume":"13","author":"Janini","year":"1988","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jaad.2008.06.004_bib121","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib122","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/keg137","article-title":"Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia","volume":"42","author":"Rey","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib123","first-page":"2090","article-title":"Raynaud's phenomenon and serotonin reuptake inhibitors","volume":"31","author":"Garcia-Porrua","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib124","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib125","first-page":"CD000954","article-title":"Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2008.06.004_bib126","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib127","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan therapy for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib128","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/rheumatology\/keg050","article-title":"Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan","volume":"42","author":"Humbert","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib130","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/rheumatology\/keh340","article-title":"Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis","volume":"43","author":"Ramos-Casals","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib131","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0755-4982(06)74645-0","article-title":"Bosentan for treatment of active digital ulcers in patients with systemic sclerosis","volume":"35","author":"Launay","year":"2006","journal-title":"Presse Med"},{"key":"10.1016\/j.jaad.2008.06.004_bib132","unstructured":"Patheon, Inc. Tracleer. Available from: URL:http:\/\/www.fda.gov\/medwatch\/SAFETY\/2003\/03Oct_PI\/Tracleer_PI.pdf. Accessed October 25, 2006."},{"key":"10.1016\/j.jaad.2008.06.004_bib133","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.vph.2006.03.004","article-title":"Does rapid dose titration affect the hepatic safety profile of Bosentan?","volume":"44","author":"Suntharalingam","year":"2006","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.jaad.2008.06.004_bib134","unstructured":"Patheon, Inc. Tracleer. Available from: URL:http:\/\/www.fda.gov\/MedWatch\/safety\/2006\/TracleerPI_012006.pdf. Accessed October 25, 2006."},{"key":"10.1016\/j.jaad.2008.06.004_bib135","first-page":"CD000956","article-title":"Prazosin for Raynaud's phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2008.06.004_bib136","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1002\/art.20665","article-title":"Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study","volume":"50","author":"Wise","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib137","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/14779072.3.3.441","article-title":"ROCKs as therapeutic targets in cardiovascular diseases","volume":"3","author":"Rikitake","year":"2005","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jaad.2008.06.004_bib138","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/hc1002.105938","article-title":"Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina","volume":"105","author":"Masumoto","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2008.06.004_bib139","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1227\/01.NEU.0000147975.24556.BC","article-title":"Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride","volume":"56","author":"Tanaka","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jaad.2008.06.004_bib140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","article-title":"Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension","volume":"91","author":"Fukumoto","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jaad.2008.06.004_bib141","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1253\/circj.70.174","article-title":"Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension","volume":"70","author":"Ishikura","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.jaad.2008.06.004_bib142","first-page":"499","article-title":"Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study","volume":"18","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib143","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/ard.2003.014431","article-title":"Low dose warfarin treatment for calcinosis in patients with systemic sclerosis","volume":"63","author":"Cukierman","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.06.004_bib144","first-page":"260","article-title":"Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasminogen activator","volume":"17","author":"Lakshminarayanan","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.1780330218","article-title":"Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy","volume":"33","author":"Fritzler","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib146","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/000331979304400709","article-title":"Tissue plasminogen activator treatment of digital thrombosis in severe Raynaud's phenomenon\u2013a case report","volume":"44","author":"Bridges","year":"1993","journal-title":"Angiology"},{"key":"10.1016\/j.jaad.2008.06.004_bib147","first-page":"2257","article-title":"Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study","volume":"28","author":"Sambo","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib148","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/rheumatology\/38.4.309","article-title":"Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon","volume":"38","author":"Denton","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.06.004_bib149","first-page":"349","article-title":"A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis","volume":"18","author":"Herrick","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib150","doi-asserted-by":"crossref","first-page":"H2124","DOI":"10.1152\/ajpheart.2001.281.5.H2124","article-title":"Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons","volume":"281","author":"Morris","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib151","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin A","volume":"119","author":"Van Beek","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2008.06.004_bib152","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0950-821X(88)80070-7","article-title":"An epidemiological survey of Raynaud's phenomenon","volume":"2","author":"de Trafford","year":"1988","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jaad.2008.06.004_bib153","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0950-821X(05)80447-5","article-title":"The role of sympathectomy in current surgical practice","volume":"8","author":"Gordon","year":"1994","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jaad.2008.06.004_bib154","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1067\/mva.2002.123330","article-title":"Endoscopic thoracic sympathicotomy for Raynaud's phenomenon","volume":"36","author":"Matsumoto","year":"2002","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jaad.2008.06.004_bib155","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0363-5023(80)80104-3","article-title":"Digital artery sympathectomy","volume":"5","author":"Flatt","year":"1980","journal-title":"J Hand Surg [Am]"},{"key":"10.1016\/j.jaad.2008.06.004_bib156","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/jhsu.2002.35887","article-title":"Adventitial stripping of the radial and ulnar arteries in Raynaud's disease","volume":"6","author":"Balogh","year":"2002","journal-title":"J Hand Surg [Am]"},{"key":"10.1016\/j.jaad.2008.06.004_bib157","first-page":"1286","article-title":"Digital sympathectomy for refractory Raynaud's phenomenon in an adolescent","volume":"19","author":"Drake","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib158","first-page":"269","article-title":"Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomenon","volume":"25","author":"Yee","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib159","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0072-968X(83)80047-3","article-title":"Superselective digital sympathectomy in Raynaud's phenomenon","volume":"15","author":"Egloff","year":"1983","journal-title":"Hand"},{"key":"10.1016\/j.jaad.2008.06.004_bib160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/micr.1013","article-title":"Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results","volume":"21","author":"Tomaino","year":"2001","journal-title":"Microsurgery"},{"key":"10.1016\/j.jaad.2008.06.004_bib161","first-page":"102","article-title":"Ulnar artery involvement in systemic sclerosis (scleroderma)","volume":"29","author":"Taylor","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib162","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1054\/jhsb.2000.0439","article-title":"Digital arterial occlusion in scleroderma: is there a role for digital arterial reconstruction?","volume":"25","author":"Tomaino","year":"2000","journal-title":"J Hand Surg [Br]"},{"key":"10.1016\/j.jaad.2008.06.004_bib163","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0895-4356(99)00005-0","article-title":"Association between cigarette and alcohol consumption and Raynaud's phenomenon","volume":"52","author":"Palesch","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2008.06.004_bib164","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/art.10685","article-title":"Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis","volume":"46","author":"Harrison","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib165","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/art.1780290822","article-title":"Successful treatment of Raynaud's phenomenon with pentoxifylline","volume":"29","author":"Goldberg","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.06.004_bib166","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archderm.1970.04000030075012","article-title":"Skin temperature changes in Raynaud's disease after griseofulvin","volume":"101","author":"Charles","year":"1970","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.06.004_bib167","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0140-6736(71)90219-4","article-title":"Griseofulvin in Raynaud's phenomenon","volume":"2","author":"Allen","year":"1971","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208006531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208006531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:10:47Z","timestamp":1759270247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962208006531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":167,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0190962208006531"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2008.06.004","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raynaud's phenomenon: Pathogenesis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2008.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}